COVID-19大流行期间肺结节管理与肺癌筛查:CHEST专家小组报告
由24名专家(17名呼吸科、5名胸部放射科、2名胸外科)组成的专家组,基于现有指南证据,通过视频会议讨论并投票(预设共识阈值为70%同意或强烈同意)制定了12条共识声明,涉及基线及年度肺癌筛查、肺结节监测、中高危肺结节评估及临床I期非小细胞肺癌管理。共识认为疫情期间可适当推迟筛查入组、推迟结节监测影像并减少非紧急干预,但需考虑本地、区域及患者相关因素。
要点
- 疫情期间可适当推迟肺癌筛查入组及肺结节监测影像。
- 中高危肺结节评估中可减少非紧急干预。
- 应用共识需结合本地、区域及患者相关因素。
诊断标准与关键数值
- 共识判定标准为预设阈值70%的专家组成员投票同意或强烈同意。
- 12条声明全部按投票结果确认为共识声明。
- 声明涉及基线及年度肺癌筛查2条、既往检出肺结节监测5条、中高危肺结节评估4条、临床I期非小细胞肺癌管理1条。
临床应用与阅片要点
- 共识声明提供指导:在认为合适的情况下可推迟筛查、推迟肺结节监测影像、减少肺结节及I期非小细胞肺癌评估中的非紧急干预。
- 将共识声明应用于个体患者时,应考虑多种本地、区域及患者相关因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: The risks from potential exposure to coronavirus disease 2019 (COVID-19), and resource reallocation that has occurred to combat the pandemic, have altered the balance of benefits and harms that informed current (pre-COVID-19) guideline recommendations for lung cancer screening and lung nodule evaluation. Consensus statements were developed to guide clinicians managing lung cancer screening programs and patients with lung nodules during the COVID-19 pandemic.
MATERIALS AND METHODS: An expert panel of 24 members, including pulmonologists (n = 17), thoracic radiologists (n = 5), and thoracic surgeons (n = 2), was formed. The panel was provided with an overview of current evidence, summarized by recent guidelines related to lung cancer screening and lung nodule evaluation. The panel was convened by video teleconference to discuss and then vote on statements related to 12 common clinical scenarios. A predefined threshold of 70% of panel members voting agree or strongly agree was used to determine if there was a consensus for each statement. Items that may influence decisions were listed as notes to be considered for each scenario.
RESULTS: Twelve statements related to baseline and annual lung cancer screening (n = 2), surveillance of a previously detected lung nodule (n = 5), evaluation of intermediate and high-risk lung nodules (n = 4), and management of clinical stage I non-small cell lung cancer (n = 1) were developed and modified. All 12 statements were confirmed as consensus statements according to the voting results. The consensus statements provide guidance about situations in which it was believed to be appropriate to delay screening, defer surveillance imaging of lung nodules, and minimize nonurgent interventions during the evaluation of lung nodules and stage I non-small cell lung cancer.
CONCLUSION: There was consensus that during the COVID-19 pandemic, it is appropriate to defer enrollment in lung cancer screening and modify the evaluation of lung nodules due to the added risks from potential exposure and the need for resource reallocation. There are multiple local, regional, and patient-related factors that should be considered when applying these statements to individual patient care.© 2020 RSNA; The American College of Chest Physicians, published by Elsevier Inc; and The American College of Radiology, published by Elsevier Inc.
引用
- Mazzone PJ, Gould MK, Arenberg DA, et al. Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report. Radiol Imaging Cancer. 2020. PMID: 33778716. doi:10.1148/rycan.2020204013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。